Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients.
OBJECTIVE
To review the current reproductive advances in insulin-sensitizing agents for treatment of polycystic ovary syndrome patients.


RESULTS
To date, among insulin-sensitizing drugs, only metformin should be used to improve reproductive function in well selected polycystic ovary syndrome patients. Preliminary data seem to show beneficial effects of thiazolidinediones in improving metabolic and hormonal patterns and in restoring regular menses.


CONCLUSIONS
The use of insulin-sensitizing drugs offers a new perspective for the treatment of polycystic ovary syndrome-related reproductive disorders. However, further data are needed before we can draw definitive conclusions regarding their clinical role.
Palomba
Stefano
S
Department of Obstetrics & Gynecology, University Magna Graecia of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
Falbo
Angela
A
Orio
Francesco
F
Zullo
Fulvio
F
D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced*; D011256:Pregnancy Outcome; D016032:Randomized Controlled Trials as Topic
D007004:Hypoglycemic Agents; D008687:Metformin